0001493152-26-016816.txt : 20260415 0001493152-26-016816.hdr.sgml : 20260415 20260415161507 ACCESSION NUMBER: 0001493152-26-016816 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260415 DATE AS OF CHANGE: 20260415 EFFECTIVENESS DATE: 20260415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulmatrix, Inc. CENTRAL INDEX KEY: 0001574235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 461821392 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-580597 FILM NUMBER: 26864313 BUSINESS ADDRESS: STREET 1: 945 CONCORD STREET STREET 2: SUITE 1217 CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: (888) 355-4440 MAIL ADDRESS: STREET 1: 945 CONCORD STREET STREET 2: SUITE 1217 CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: Ruthigen, Inc. DATE OF NAME CHANGE: 20130411 D 1 primary_doc.xml X0708 D LIVE 0001574235 Pulmatrix, Inc. 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 (888) 355-4440 DELAWARE None Ruthigen, Inc. Corporation true Michael Higgins 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 Director Todd Bazemore 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 Director Richard Batycky 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 Director Christopher Cabell 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 Director Anand Varadan 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 Director Peter Ludlum 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA MASSACHUSETTS 01701 Executive Officer Interim CEO; Interim CFO Biotechnology Decline to Disclose 06b false 2026-03-26 false true true In connection with the signing of the Merger Agreement with Eos SENOLYTIX, Inc. 1000000 None None None None None None None XX Unknown XX TX TEXAS false 1000000 1000000 0 The issuer issued 1,000 shares of Series B Convertible Preferred Stock, stated value $1,000 per share for aggregate proceeds of $1,000,000 in a private placement pursuant to Rule 506(b) of Regulation D. false 1 0 0 0 false Pulmatrix, Inc. /s/ Peter Ludlum Peter Ludlum Interim CEO, Interim CFO 2026-04-15